Editing Nootropic (section)

== Availability and prevalence ==
In 2008, stimulants, such as caffeine, were the most commonly used nootropic agent.<ref name="Nature2008">{{cite journal | vauthors = Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ | title = Towards responsible use of cognitive-enhancing drugs by the healthy | journal = Nature | volume = 456 | issue = 7223 | pages = 702–705 | date = December 2008 | pmid = 19060880 | doi = 10.1038/456702a | s2cid = 3598099 | bibcode = 2008Natur.456..702G | oclc = 01586310 | url = https://pure.manchester.ac.uk/ws/files/28322116/POST-PEER-REVIEW-PUBLISHERS.PDF }}</ref> In 2016, the [[American Medical Association]] adopted a policy to discourage prescriptions of nootropics for healthy people, on the basis that the cognitive effects appear to be highly variable among individuals, are dose-dependent, and limited or modest at best.<ref name="ama">{{cite web |title=AMA confronts the rise of nootropics |url=https://www.ama-assn.org/press-center/press-releases/ama-confronts-rise-nootropics |publisher=American Medical Association |access-date=May 12, 2019 |date=June 14, 2016}}</ref> [[Piracetam]], [[N-Phenylacetyl-L-prolylglycine ethyl ester|noopept]] and [[meclofenoxate]] have been sold as dietary supplements.<ref name="NeuroClin"/><ref name="JAMAIM"/><ref>{{cite journal | vauthors = Cohen PA, Avula B, Khan I | title = The unapproved drug centrophenoxine (meclofenoxate) in cognitive enhancement dietary supplements | journal = Clinical Toxicology | volume = 60 | issue = 10 | pages = 1156–1158 | date = October 2022 | pmid = 35959800 | doi = 10.1080/15563650.2022.2109485 | s2cid = 251516603 }}</ref>